Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

CNS Depressants: Alcohol and Nicotine

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...

Depressants

Depressants

Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...

Opioid Receptors: Overview

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Changes in leukocytes and CRP in different treatments of major depression.

Journal of neural transmission (Vienna, Austria : 1996)·2026

Same author

Efficacy, moderators and mediators of cognitive behavioural analysis system of psychotherapy (CBASP) versus behavioural activation (BA) in persistently depressed treatment-resistant inpatients: study protocol for the multicentre, randomised controlled <i>changePDD</i> trial.

BMJ open·2026

Same author

Differential DNA-methylation of synaptic genes in CSF and blood in schizophrenia.

Schizophrenia (Heidelberg, Germany)·2026

Same author

A randomized controlled trial of an interactive digital therapeutic for stress and burnout management.

Npj mental health research·2025

Same author

Decision tree-based approach to robust Parkinson's disease subtyping using clinical data of the Michael J. Fox Foundation LRRK2 cross-sectional study.

Frontiers in artificial intelligence·2025

Same author

Epigenetic alterations of serotonergic but not dopaminergic signalling in compulsive sexual behaviour disorder.

Behavioural brain research·2025

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

Opioid modulators for alcohol dependence.

Thomas Hillemacher¹, Annemarie Heberlein, Marc An Muschler

¹Hannover Medical School, Center for Addiction Research (CARe) , Department for Psychiatry , Socialpsychiatry and Psychotherapy, Carl-Neuberg-Str. Germany. hillemacher.thomas@mh-hannover.de

Expert Opinion on Investigational Drugs

|June 10, 2011

Summary

Opioid antagonists like naltrexone can help reduce heavy drinking by targeting the brain's opioid and dopamine systems. Further research is ongoing for new medications to treat alcohol dependence.

More Related Videos

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

Published on: April 28, 2022

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

Related Experiment Videos

Last Updated: Jun 1, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

Published on: April 28, 2022

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

Area of Science:

Neuroscience
Pharmacology
Addiction Medicine

Background:

The endogenous opioid system significantly influences drinking behavior.
Opioid modulators impact the dopamine system and central nervous system (CNS) stress response.

Purpose of the Study:

To review the opioid system's role in alcohol dependence.
To explore neurobiological mechanisms of pharmacological interventions for alcohol use disorder.

Main Methods:

Comprehensive literature search of Medline and internet resources.
Critical assessment and interpretation of existing and emerging opioid modulators.
Focus on individualized therapy for alcohol dependence.

Main Results:

The opioid system is vital in the development and persistence of alcohol dependence.
Naltrexone demonstrates efficacy in treating alcohol dependence by modulating CNS opioidergic transmission.
Nalmefene shows some efficacy, while newer agents (e.g., LY2196044, ALKS-29, ALKS-33) require further clinical validation.

Conclusions:

Opioid system modulation is key for alcohol dependence treatment.
Naltrexone is an established pharmacological tool, with newer agents under investigation.
Individualized treatment strategies incorporating opioid modulators are crucial.